APOTEX CORP. for APOTEX CORP.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Federal policy relating to federal procurement country of origin requirements for pharmaceuticals.
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Copyright/Patent/Trademark CPT
HR 9, The Innovation Act, provisions in Section 9, Improvements and Technical Corrections to the Leahy-Smith America Invents Act, including federal policy relating to inter partes review challenges of pharmaceutical and biotechnology patents; and S 1137, The Patent Act, provisions in Section 14, Technical Corrections to the Leahy-Smith American Invents Act and other improvements, including federal policy relating to the use of inter partes review challenges of pharmaceutical and biotechnology patents.
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Pharmacy PHA
HR 6, The 21st Century Cures Act, provisions relating to the discovery, approval and manufacturing of pharmaceuticals; Federal policy relating to issues affecting the generic drug industry within the Senate Health, Education, Labor and Pensions Committee's Innovation for Healthier Americans initiative; HR 2841, The FAST Generics Act of 2015, provisions relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing; S 131, The FAIR Generics Act, provisions relating to market blockages caused by "parked" 180 day exclusivity periodd, and; S. 2019, The Preserve Access to Affordable Generics Act, provisions relating to the legality of patent settlements between brand and generic pharmaceutical companies; Federal policy relating to the Implementation of Public Law 112-144, The Food and Drug Administration Safety and Innovation Act, Title 3, Fees Relating to Generic Drugs.
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Medicare/Medicaid MMM
HR 1314, The Bipartisan Budget Act of 2015, Title VI, Section 602, provisions relating to Medicaid rebates for generic drugs.
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.